FDA WARNING_LETTER - Oralabs Inc. - September 26, 2025

OraLabs, Inc., an over-the-counter (OTC) drug product manufacturer, received an FDA Warning Letter following an inspection from September 22 to 26, 2025, at its Parker, Colorado facility. The letter identified significant violations of Current Good Manufacturing Practice (CGMP) regulations, leading to the conclusion that the company"s drug products are adulterated under the Federal Food, Drug, and Cosmetic Act. A key violation was the firm"s failure to conduct appropriate microbiological testing for each batch of drug product, releasing multiple OTC products without necessary microbial release testing. OraLabs incorrectly asserted that such testing was not required for their product type, despite FDA"s past experience with recalls involving similar products. Additionally, the company failed to thoroughly investigate unexplained discrepancies or failures, particularly regarding microbiological testing. Investigations into microbial excursions were frequently inadequate, lacking robust root cause analysis and appropriate corrective actions. The firm often invalidated positive test results without sufficient scientific justification, inappropriately minimizing contamination risks. The FDA mandates OraLabs provide a comprehensive independent assessment of its laboratory practices and manufacturing operations, including detailed remediation plans. This encompasses an action plan for full chemical and microbiological testing of all in-expiry retain samples, a summary of results, and outlined corrective actions for any out-of-specification findings. Furthermore, OraLabs must conduct a detailed risk assessment concerning the distribution of potentially contaminated products and complete thorough investigations into all past microbial excursions. The company must respond within 15 working days detailing its corrective actions.